CALR and essential thrombocythemia: Previously, the frequencies of CALR exon 9 mutations in MPN patients without JAK2 or MPL mutation were reported to 67% in ET patients and 88% in PMF patients in one study [9], and 82% in ET patients and 80% in PMF patients in other study [10].